Aloka takes over U.S. sales from Corometrics
Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka
Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka soldits scanners in radiology and intraoperative markets and Corometricsmaintained exclusive U.S. sales and marketing rights to Alokascanners in the ob/gyn and veterinary markets. Both firms arebased in Wallingford, CT.
The new structure enables the two firms to be more responsiveto customers by allowing each to focus on its core area of expertise-- Aloka in ultrasound and Corometrics in monitoring products-- according to James Pietropaolo, vice president of sales andmarketing. Corometrics will continue to provide service for allAloka ultrasound products in the U.S.
In other Aloka news, the company has announced its MultiViewupgrade for the SSD-2000 ultrasound scanners. The upgrade improvesgray-scale and color Doppler performance and includes a PowerFlowDoppler feature. All SSD-2000 units in the field are upgradableto MultiView and Aloka in August shifted production to new SSD-2000MultiView scanners.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
